摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-溴-1,2-苯并异恶唑 | 837392-65-1

中文名称
5-溴-1,2-苯并异恶唑
中文别名
5-溴-1,2-苯并异噁唑
英文名称
5-bromobenzo[d]isoxazole
英文别名
5-Bromo-1,2-benzisoxazole;5-bromo-1,2-benzoxazole
5-溴-1,2-苯并异恶唑化学式
CAS
837392-65-1
化学式
C7H4BrNO
mdl
——
分子量
198.019
InChiKey
XAGKLUNARLSYDT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    276.1±13.0 °C(Predicted)
  • 密度:
    1.710±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    26
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:d20248098617cfeb4572f58851b56fc5
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5-Bromo-1,2-benzisoxazole
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-1,2-benzisoxazole
CAS number: 837392-65-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H4BrNO
Molecular weight: 198.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

点击查看最新优质反应信息

文献信息

  • Lewis Acid‐Catalyzed [4+2] Annulation between Propargylic Alcohols with Benzo[ <i>d</i> ]isoxazoles
    作者:Ya‐Ping Han、Xue‐Song Li、Zhou Sun、Xin‐Yu Zhu、Ming Li、Xian‐Rong Song、Yong‐Min Liang
    DOI:10.1002/adsc.201700495
    日期:2017.8.17
    An unprecedented copper(II) trifluoromethanesulfonate‐catalyzed [4+2] cascade annulation of propargylic alcohols with benzo[d]isoxazoles proceeds through a sequential ring opening/Meyer–Schuster rearrangement/intermolecular cyclization. This protocol, which tolerates a broad variety of functional groups, offers a versatile, modular and atom‐economical access to a new class of fascinating quinoline
    前所未有的三氟甲磺酸铜(II)催化的炔丙醇与苯并[ d ]异恶唑的级联环化反应通过顺序开环/ Meyer-Schuster重排/分子间环化来进行。该方案可耐受多种官能团,在温和条件下以高收率提供了一种通用的,模块化的,原子经济的途径来获得新型迷人的喹啉衍生物。转换可以有效地放大到克级,从而突出了此方法的综合效用。
  • [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES<br/>[FR] INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE POUR LE TRAITEMENT DE MALADIES
    申请人:BIOMARIN PHARM INC
    公开号:WO2015042397A1
    公开(公告)日:2015-03-26
    Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).
    本文描述了一种I式化合物,制备这种化合物的方法,含有这种化合物的药物组合物和药物,以及使用这种化合物治疗或预防与葡萄糖酰胺合成酶(GCS)相关的疾病或症状的方法。
  • Gold-Catalyzed Michael-Type Reactions and [4 + 2]-Annulations between Propiolates and 1,2-Benzisoxazoles with Ester-Directed Chemoselectivity
    作者:Yashwant Bhaskar Pandit、Rajkumar Lalji Sahani、Rai-Shung Liu
    DOI:10.1021/acs.orglett.8b02663
    日期:2018.11.2
    This work reports gold-catalyzed reactions between 1,2-benzisoxazoles and propiolate derivatives with ester-controlled chemoselectivity. For ethyl propiolates 1′, their gold-catalyzed reactions afforded Michael-type products 4, whereas tert-butyl propiolates 1 preferably underwent [4 + 2]-annulations, further yielding 6H-1,3-oxazin-6-one derivatives 3.
    这项工作报告了1,2-苯并恶唑与丙酸酯衍生物之间的金催化反应,并具有酯控制的化学选择性。对于丙酸乙酯1',其金催化的反应得到迈克尔型产物4,而丙酸叔丁酯1优选经历[4 + 2]环化,进一步产生6 H -1,3-恶嗪-6-一衍生物3。
  • Thienopyridine and furopyridine kinase inhibitors
    申请人:Betschmann Patrick
    公开号:US20050026944A1
    公开(公告)日:2005-02-03
    Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    具有以下化学式的化合物对抑制蛋白酪氨酸激酶具有用处。本发明还公开了制备这些化合物的方法、含有这些化合物的组合物,以及使用这些化合物进行治疗的方法。
  • An efficient synthesis of oxazolines <i>via</i> a cascade reaction between azaoxyallyl cations and 1,2-benzisoxazoles
    作者:Li Sun、Yi Liu、Yankai Wang、Yuanyuan Li、Zhiwen Liu、Tao Lu、Wenhai Li
    DOI:10.1039/c9ob01366k
    日期:——
    A formal [3 + 2] cycloaddition reaction between the C and O terminals of azaoxyallyl cations formed in situ and 1,2-benzisoxazoles has been realized. This one-pot cycloaddition method provided an effective and practical pathway to synthesize oxazoline in good yields under mild conditions. The title products exhibited unique fluorescence properties.
    已经实现了在原位形成的氮杂烯丙基阳离子的C和O末端与1,2-苯并恶唑之间的正式[3 + 2]环加成反应。这种一锅法环加成法为在温和条件下以高收率合成恶唑啉提供了有效而实用的途径。标题产物表现出独特的荧光性质。
查看更多

同类化合物

苯并异恶唑Hsp90抑制剂 苯并[d]异噁唑-7-醇 苯并[d]异噁唑-5-胺 苯并[d]异噁唑-5-磺酰氯 苯并[D]异恶唑-3-甲酸 苯[D]异恶唑-3-醇 羟基伊洛哌酮 甲基6-氨基-1,2-苯并恶唑-3-羧酸酯 环己酮,2,3-二甲基-6-(1-甲基乙基)-,[2R-(2α,3ba,6ba)]-(9CI) 帕潘立酮杂质1 奈氟齐特 四氢-4-[[[4-[[[4-[[(3R)-四氢-3-呋喃基]氧基]-1,2-苯并恶唑-3-基]氧基]甲基]-1-哌啶基]甲基]-2H-吡喃-4-醇 唑尼酰胺-d4 唑尼沙胺钠 唑尼沙胺13C2-15N 唑尼沙胺 呋喃并[3,4:3,4]环丁二烯并[1,2:3,4]环丁二烯并[1,2-d]异噻唑(9CI) 呋喃并[3,4-f][1,2]苯并恶唑 呋喃并[3,4-e][1,2]苯并恶唑 呋喃并[3,2-g][1,2]苯并恶唑 呋喃并[3,2-f]-1,2-苯并异恶唑 呋喃并[2,3-f][1,2]苯并恶唑 呋喃并[2,3-e][1,2]苯并恶唑 叔-丁基(6-溴苯并[D]异噻唑-3-基)氨基甲酯 化合物 T29498 佐尼氯唑 伊潘立酮(R)-羟基杂质 alpha-甲基-3-苯基-1,2-苯并异恶唑-7-乙酸 [1,2]恶唑并[5,4-f][1,2]苯并恶唑 [1,2]恶唑并[5,4-e][2,1,3]苯并恶二唑 [1,1'-联苯基]-3-醇,2'-(5-乙基-3,4-二苯基-1H-吡唑-1-基)- [(3-氨基-1,2-苯并异恶唑-5-基)甲基]氨基甲酸叔丁酯 N,N-二甲基唑尼沙胺杂质 N-甲氧基-N-甲基苯并[d]异恶唑-3-甲酰胺 N-甲基唑尼沙胺 N-乙基苯异恶唑酮四氟硼酸盐 N-[(1,2-苯并恶唑-3-基甲基)磺酰基]乙酰胺 N-(苯并[D]异恶唑-3-基氧基-二甲基氨基-磷酰)-N-甲基-甲胺 N-(6-己酸)唑尼沙胺 7-硝基-1,2-苯并恶唑 7-甲氧基-3-甲基-1,2-苯并恶唑 7-甲基苯并[d]异恶唑-3-醇 7-溴苯并[d]异噁唑 7-溴苯并[D]异恶唑-3(2H)-酮 7-溴-3-氯苯并[D]异恶唑 7-溴-1,2-苯并恶唑-3-胺 7-氯-苯并[d]异恶唑 7-氟苯并[d]异噁唑-3-胺 7-氟-苯并[d]异噁唑-3-醇 6-苯基苯并[d]异噁唑-3-胺